

PERFORMANCE OF APOSTLE TECHNOLOGY INDEPENDENTLY VALIDATED

For immediate release

San Jose, CA, January 28, 2022

A recent independent study conducted by scientists from Johns Hopkins University and University of Pittsburgh, published in a peer-reviewed journal *SLAS Technology*, showed that, "(Page 6, Figure 4) Most notably, the Apostle particles outperformed all others, achieving almost 2-fold higher recovery yields than the particles supplied in the X kit".




Figure 4. Comparison of DNA yields using silica-magnetic particles from different manufacturer. Extracted DNA yields when using different silica-coated magnetic particles with Qiagen extraction reagents (gDNA) and bisulfite conversion with the Zymo Lightning Conversion kit (bstDNA).

6

SLAS Technology is a peer-reviewed scientific journal published by the Society for Laboratory Automation and Screening in partnership with SAGE Publications. In this study, Stark *et al.* - independent researchers from Johns Hopkins University and University of Pittsburgh- seek to develop an integrated, automated solution for performing the entire sample preparation process, including DNA extraction, purification, bisulfite conversion and PCR plate preparation within in an enclosed environment. They also compared commercial DNA extraction and bisulfite conversion kits to identify a protocol suitable for automation to significantly improve genomic and bisulfite-treated DNA yields over manufacturer protocols. The article is titled "High-throughput sample processing for methylation analysis in an automated, enclosed environment".

This work joins the line of research work to independently validate the best-in-class of Apostle MiniMax nanoparticle technology in the application of liquid biopsy, including its utility in methylation analysis. Apostle did not participate in or sponsor this study.

Read this article: <https://www.sciencedirect.com/science/article/pii/S2472630321000248>

About Apostle Inc and Apostle Diagnostics

Apostle Inc is a biotechnology company in San Jose, CA, a provider of innovative technologies and services for public health and life sciences. Apostle aims to develop innovative technologies in the space of liquid biopsy - the sampling and analysis of non-solid biological tissue, primarily blood, often utilizing circulating free DNA (cfDNA) as a biomarker. Apostle's innovations include Apostle MiniMax, a new scalable and automatable method to efficiently capture cfDNA from a standard blood draw; Apostle MagTouch, a nucleic acids isolation automation system, and Apostle MiniEnrich, a high-resolution DNA size enrichment technology using a magnetic nano-platform. Since 2020, the company has responded to the COVID-19 pandemic to help our community fight together with a high quality, low cost, fast, automated, Apostle COVID-19 Viral RNA Isolation System. Up to date, Apostle's technology has served over 15 million people.

Apostle Diagnostics a CLIA Certified, California State Licensed, CAP Accredited Clinical Laboratory, and is a clinical laboratory branch of Apostle Inc. The laboratory is co-directed by Wenqi Zeng, MD, PhD, FACMG and Charles Strom, MD, PhD, FAAP, FACMG, HCLD. The laboratory upholds the people-oriented and science-oriented service concept and is committed to serving the community and providing accurate, strict and timely clinical testing services. To date, Apostle Diagnostics has served more than 50,000 people.

More information can be found at www.apostle.bio ; www.apostledx.com.

Contact: info@apostlebio.com